Oppenheimer lifts Xylem shares target, cites strong growth framework By Investing.com

On Friday, Oppenheimer maintained a positive stance on Xylem (NYSE: NYSE:) shares, increasing the price target to $152 from the previous $147 while keeping an Outperform rating on the stock.

The firm’s confidence in the company has grown following the attendance of Xylem’s 2024 Investor Day held in the US capital. Xylem’s CEO, Matthew Pine, along with the senior leadership team, showcased the company’s successful realization of the goals set during the 2021 Investor Day.

They also highlighted the early-stage success of the Xylem-Evoqua integration and introduced their growth framework for the years 2024-2027.

The leadership team’s presentation underscored Xylem’s strong competitive position, marked by unmatched scale and a broad portfolio of technologies and services. The company’s prospects for sustained earnings growth over the upcoming years were a focal point of the event.

The analyst from Oppenheimer expressed a belief that the medium-term financial targets, which include a mid-teens compound annual growth rate (CAGR) in earnings per share (EPS), might be on the conservative side, given the robust demand backdrop and the expanding economic moats around Xylem’s business.

The revised price target of $152 is based on a 19.5 times enterprise value to earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) multiple on Oppenheimer’s 2025 earnings estimate.

This valuation represents a slight premium compared to the average of Xylem’s competitors, yet it is modestly below the company’s current 2024 earnings multiple.

The positive outlook reflects the analyst’s view that Xylem is well-positioned to capitalize on its strategic initiatives and market position in the coming years.

InvestingPro Insights

Analysts and investors seeking a deeper dive into Xylem’s financial health and future prospects can turn to InvestingPro for real-time data and professional insights. Currently, Xylem’s market capitalization stands at a robust $33.8 billion, reflecting the scale and investor confidence in the company. The high P/E ratio of 48.98 indicates that investors are willing to pay a premium for Xylem’s earnings, which could be justified by the company’s consistent dividend growth, now in its 13th consecutive year, and the recent upward earnings revisions by 8 analysts for the upcoming period. This enthusiasm is further supported by the company’s impressive revenue growth over the last twelve months, clocking in at 39.51%.

InvestingPro Tips reveal that Xylem is trading at a high earnings multiple relative to near-term earnings growth and operates with a moderate level of debt, suggesting a balanced approach to leverage and growth. Furthermore, with liquid assets exceeding short-term obligations, the company appears to be in a good position to meet its immediate financial commitments. For those interested in additional insights, there are 15 more InvestingPro Tips available, which can provide a more comprehensive understanding of Xylem’s financial situation and market potential. Readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro, where they can access these valuable tips and metrics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.